drug_type
RELEVANT_DRUG
intervention_type
Vaccine
drug_description
Long-peptide therapeutic cancer vaccine derived from CMV pp65 (26-aa) containing MHC I/II epitopes to induce CMV-specific CD8+ and CD4+ T-cell responses against CMV-expressing glioblastoma cells.
nci_thesaurus_concept_id
C107243
nci_thesaurus_preferred_term
PEP-CMV Vaccine
nci_thesaurus_definition
A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance.
drug_mesh_term
Cytomegalovirus Vaccines
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Intradermal
drug_mechanism_of_action
Long-peptide vaccine derived from CMV pp65 (26-aa) containing MHC I/II epitopes; following administration, antigen-presenting cells present these epitopes to activate and expand CMV-specific CD8+ cytotoxic and CD4+ helper T cells, enabling immune recognition and killing of CMV-expressing glioblastoma cells.
drug_name
PEP-CMV vaccine
nct_id_drug_ref
NCT06132438